COHANCE Cohance Lifesciences Q2 FY26 results (Jul–Sep 2025) and concall
Management summary
- Cohance Lifesciences used its Q2 FY26 update call to announce a significant organizational restructuring following the resignation of its Managing Director.
- The company is moving toward a vertical-led structure with three new business CEOs reporting to the Executive Chairman to accelerate its $1 billion revenue target for 2030.
- While no financial results were disclosed due to a silent period, management highlighted strong momentum in the CDMO pipeline, including a key Phase 3 win from a Japanese client.
Source: Inve concall analysis and management guidance record.
What they filed
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|
| Revenue | 676 | 840 | 549 | 556 |
| EBITDA | 237 | 229 | 112 | 121 |
| Net profit | 153 | 117 | 46 | 66 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Guidance & targets
2Revenue
Total Revenue Vision Revenue · by 2030 · High confidence US$1 billion
Capacity
Oligonucleotide Unit Commissioning Capacity · Q4 FY26 · High confidence Commissioned
Source: Inve Guidance Tracker — management targets and direct quotes from the earnings call transcript.
Q&A highlights
2Leadership Churn and Transition Management Direct
There is no single dependency on Dr. Prasada on any specific client. All these relationships were already transferred as part of normal transition to the business CEOs.
Investors were concerned about client retention following the MD's exit; management clarified that the new vertical CEOs already own these relationships.
Asked by Chirag Dagli, DSP Asset Managers
Cultural Integration of Six Entities Direct
Somebody started saying we are a combination of six family-owned businesses that have now become part of who we are today... there is definitely a transition in culture.
Highlights the execution risk of merging multiple legacy cultures into a single corporate platform, which management acknowledges as an ongoing journey.
Asked by Karthikeyan, Suyash Advisors
Unlock risks & concerns, Q3 FY26 watchlist, and full call analysis
You’re reading a preview. Opening the full call uses 1 concall credit and unlocks:
- 3 risks, concerns & management red flags
- Watchlist triggers for Q3 FY26
- +1 more guidance target & verbatim management quotes
- +1 more analyst Q&A exchange & evasion checks
- Full section-by-section call narrative
Sign in to use your monthly call allowance.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared and our regulatory disclaimer. · Share on WhatsApp · Scorecard image





